drugset / Trial / NCT06485232
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open label, single-site, dose-escalation study in up to 25 participants with refractory autoimmune diseases of nervous system. This study aims to evaluate the safety and efficacy of the treatment with universal BCMA and CD19 CART.
Timeline
- Start
- 2025-02-28
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Universal BCMA CAR-T | Cell therapy | — | — |
| Subject | Universal CD19 CAR-T | Cell therapy | — | — |